You are subscribed to the FormularyWatch.

Formulary

eNewsletter Subscribe

March 20, 2015

Web Version  | Share with a colleague

Facebook Like Twitter Tweet

Today's Headlines

Doing a drug-cost benefit analysis for multiple sclerosis?

Lemtrada (alemtuzumab) offers another alternative for patients who have had an inadequate response, contraindication, or are intolerant to the other multiple sclerosis therapies. Lemtrada will likely be a third- or fourth-line agent. » Details

FDA approves drug to treat rare bile acid synthesis disorders in kids, adults

FDA approved the first treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for patients with peroxisomal disorders (including Zellweger spectrum disorders). » Details

Continuing Education

2015 Updates on the national guidelines for diabetes management and related disorders

Last month and this month pharmacists will be able to learn about the latest developments in diabetes treatment and management. Pharmacists can earn up to 4 hours of CPE credit with two monthly knowledge-based activities from the University of Connecticut School of Pharmacy and Drug Topics. The goal of this month’s activity is to discuss the recent updates of national U.S. guidelines for diabetes management, including hypertension and cholesterol management in patients with diabetes, in order to empower pharmacists in clinical decision-making.

Read/print the article: Click here

Take the test: Click here to log in with the Session Code 15DT16-TAJ88.


Announcement: Our CE activities have moved to a new learning management system to better serve you. The login to the Online CE Center is https://web2.uconn.edu/pharmacyce/login.php. All current user registration information has been uploaded for your convenience. Current users do not need to register. To review your registration page to ensure the data is up to date or to register, go to https://web2.uconn.edu/pharmacyce/program_register.php. For a full list of courses, go to http://pharmacy.uconn.edu/academics/ce/drug-topics-and-uconn-ce/

EDITOR'S PICK

DEA issues alert on fentanyl after overdoses

The United States Drug Enforcement Administration (DEA) on March 18 issued a nationwide alert about the dangers of fentanyl and fentanyl analogues/compounds. » Read more

POLL:

A new class of biologics in the PCSK9 Inhibitors likely will be approved for treating high cholesterol. How are you preparing?

 

RELATED ARTICLES

Specialty pharmaceuticals roundtable: Balancing benefits, cost

FDA drug approvals

RESOURCES

Latest Clinical News

Powered by Modern Medicine Advanstar Medical Communications Group